Position in NVO
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$80,424,863
+$37,272,536 QoQ
Shares Held
1,677,615
+42.9% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.88%
of 13F equity value
Holder Rank
#40
of 1,348 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 97%
Shared 0%
None 3%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026CAUSEWAY CAPITAL MANAGEMENT LLC holds $2,118,676,056 across 8 Drug Manufacturers - General names. NVO ranks #3 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
9,357,390 | $1,774,348,291 | |
| 2 | MRK |
Merck & Co., Inc.
|
954,932 | $122,708,762 | |
| 3 | NVO |
Novo Nordisk A S
This page
|
1,677,615 | $80,424,863 | |
| 4 | BIIB |
Biogen Inc.
|
278,283 | $60,125,824 | |
| 5 | PFE |
Pfizer Inc
|
1,916,801 | $46,156,568 | |
| 6 | SNY |
Sanofi
|
804,056 | $34,301,028 | |
| 7 | GSK |
GSK plc
|
7,163 | $375,484 | |
| 8 | NVS |
Novartis AG
|
1,501 | $235,236 |
All Filings in NVO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $80,424,863 | 1,677,615 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $43,152,327 | 1,174,213 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $50,567,088 | 993,850 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $38,619,874 | 695,979 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $24,425,073 | 353,884 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||